Brief: Q32 Bio Sells Complement Inhibitor Adx-097
01/12/2025 13:03
Dec 1 (Reuters) - Q32 BIO SELLS COMPLEMENT INHIBITOR ADX-097 Q32 BIO INC - $12 MILLION PAYMENTS EXPECTED TO EXTEND CASH RUNWAY INTO SECOND HALF OF 2027 Q32 BIO INC - ELIGIBLE FOR UP TO $592 MILLION INCLUDING ROYALTIES Source text: ID:nPn4S4bM2a ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule